The activity of the renin-angiotensin system influences blood pressure (BP) and cardiovascular structure in humans. Therefore, we questioned whether left-ventricular (LV) structure and function are influenced by the Ϫ20 A/C variant of the angiotensinogen (AGT) gene in young normotensive or mildly hypertensive patients.
L
eft-ventricular hypertrophy (LVH) is a strong independent risk factor for cardiovascular morbidity and mortality. 1 In arterial hypertension, LVH is a common finding. Even in subjects with mild hypertension, the prevalence of LVH is about 20%. 2 Leftventricular hypertrophy is more closely related to 24-h ambulatory blood pressure than to casual blood pressure. However, Ͼ50% of the variance in left-ventricular mass (LVM) is not explained by the hemodynamic load. 3 The LVM is determined by the complex interaction between genetic, environmental, and lifestyle factors. Therefore, an improved understanding of the origins and pathophysiology of LVH may translate into better prevention and treatment of heart disease. The renin-angiotensin system (RAS) in particular emerged as a pivotal modulator of LVH. 4 It was shown that angiotensin II acts as a growth-stimulating and regulating factor on myocardial cells, 5, 6 and that the RAS is critically involved in long-term effects on the cardiovascular system such as structural remodeling.
Angiotensinogen (AGT) is the rate-limiting factor for the activity of RAS, and, as a consequence, AGT gene polymorphisms are of potential interest for LVH. Several polymorphisms of the AGT have been identified, but findings with regard to their functional relevance are inconsistent and controversial. 7 The promoter region of AGT received particular attention, because gene variants in this region appear to be biologically and clinically relevant. Among these genetic mutations of the AGT gene, a singlenucleotide polymorphism in the promoter region located at Ϫ20 between the TATA box and the initiation side was identified that substitutes an adenosine for a cytosine. 8 This polymorphism was associated with increased AGT transcription in vitro 9 and with elevated plasma AGT and hypertension in one study 10 but not in other studies. 11, 12 With regard to left-ventricular (LV) structure and systolic function, a relationship between plasma AGT and LVM was reported in young adults. 13 However, it is readily appreciated that indices of RAS activity measured in the systemic circulation are poor markers and do not necessarily reflect the true activity of the RAS, which is regulated by both humoral and tissue RAS activity. Thus, it appears most promising to assess the relationship between degree of target-organ damage, ie, LVH, supposedly driven by RAS activity, and its potential underlying mechanism, ie, gene variants of the AGT gene. So far, no data have been published examining LV structure and function in conjunction with the Ϫ20 A/C gene variants of the AGT gene. We questioned whether the Ϫ20 A/C polymorphism of the AGT gene is associated with LV structure and functional adaptation to elevated blood pressure in a homogenous cohort of young, male, white subjects.
Methods

Study Population
Subjects were recruited through blood-pressure screening efforts at the University of Erlangen-Nürnberg, or by advertising in local newspapers in the area of ErlangenNürnberg. Eligible subjects were consecutively enrolled. Altogether, 214 young (26.5 Ϯ 4.1 years), male, white subjects with normal, mildly elevated, or moderately elevated blood pressure (BP) were enrolled. According to the European Society of Hypertension-European Society of Cardiology guidelines of 2003 14 an average BP of Ն125 mm Hg systolic or Ն80 mm Hg diastolic in 24-h ambulatory BP was defined as reflecting a hypertensive state. Inclusion criteria included ages between 20 and 35 years, white race, and male sex. Major exclusion criteria included hyperlipidemia, diabetes mellitus, smoking, secondary or severe hypertension, current or previous treatment for arterial hypertension, or any other cardiovascular disease.
The study protocols were approved by the local Ethics Committee (University of Erlangen-Nürnberg, Erlangen, Germany), and the study was performed according to "good clinical practice" guidelines. Informed written consent was obtained before inclusion of subjects in the study.
Clinical Parameters
Blood pressure and heart rate were measured after 5 min of rest in a sitting position with an oscillometric device (Dinamap Pro100V2; Criticon, Norderstedt, Germany), and an average of the last three measurements was taken. Ambulatory 24-h BP measurements were taken with an automatic portable device (No. 90207; Spacelab, Redmont, CA). Measurement intervals consisted of every 15 min during the day (defined as 7:00 AM to 10:00 PM) and every 30 min during the night. In parallel, 24-h urinary sodium excretion, which represents a rough but valuable estimate of daily sodium intake, was measured.
15
DNA Sequencing
From genomic DNA, a 345-base-pair (bp) fragment of the human AGT gene, starting 222 bp upstream from the transcription start side, 16 was amplified by using the primers 5=-TGCACCGGCTCACTCTGTTCA-3= and 5=-ATCTCCCGGGCCTTTTCCTCCTA-3=. Thirty-five polymerase chain reaction cycles (94°C, 60°C, and 72°C, each for 1 min) were performed with a thermocycler (Hybaid Ltd, Ashford, UK). For genotyping, Dra II was used. After restriction digestion, gel electrophoresis was performed to determine cleavage of polymerase chain reaction products by the respective enzyme. All subjects were unambiguously genotyped.
Echocardiography
Two-dimensional-guided M-mode echocardiography was performed using an ultrasonoscope (Picker-Hitachi CS 192; Hitachi, Tokyo, Japan) with a 2.5-MHz probe. Details are described elsewhere. 15 All echocardiographic reading were independently evaluated by two investigators. The echocardiographic reading was performed blindly with respect to other clinical data and, in particular, to the genotyping of our subjects. Relative wall thickness was calculated as two times the diastolic posteriorwall thickness divided by the end-diastolic diameter and served as the parameter of concentric LV hypertrophy. The LV structural and functional parameters were calculated according to recommendations of the American Society of Echocardiography 17 and were corrected according to the suggestions of Devereux et al. 18 Midwall fractional fiber shortening and velocity of the circumference served as parameters for systolic function. Left ventricular diastolic filling was determined by pulsed-wave Doppler sonography of LV inflow. This was performed from the apical four-chamber view, with the volume sample placed between the mitral leaflet and the Doppler beam aligned parallel to the mitral flow. The signal was optimized by audio and visual feedback to obtain the recording with the maximum velocity, the least spectral dispersion, and the greatest signal-to-noise ratio. The peak early diastolic inflow velocity coincident with the A wave and the ratio of peak late to early velocities were measured. Furthermore, the ratio of velocity time integrals was assessed. The atrial contribution to LV filling in percentages was calculated as the velocity time integral A divided by the velocity time integral of total diastolic inflow.
Statistical Analysis
Data of clinical and echocardiographic characteristics are expressed as mean Ϯ SD. According to normal distributions of measured data, the unpaired t-test was used to detect any significant difference between subjects homozygous for the Ϫ20 A allele and those with at least one copy of the Ϫ20 C allele (AC and CC combined). A covariance analysis was performed to take into account the influence of potential confounding factors on LV structure and function. Two-tailed values of P Ͻ .05 were considered statistically significant. All analyses were performed using SPSS version 13.0 (SPSS, Inc., Chicago, IL).
Results
The distribution of Ϫ20 A/C gene variants was similar to that observed in other studies, despite the fact that we enrolled only male subjects. The frequency of subjects homozygous for the Ϫ20 A allele was 73.4%, and the frequency for those with at least one copy of the Ϫ20 C allele was 26.6% (AC with 24.7% and CC with 1.9% combined) ( Table 1) . Within all study groups, genotype distributions were consistent with Hardy-Weinberg equilibrium. Slightly more than half of our patients (52.6% of AC/CC and 57.3% of AA) were classified as hypertensive according to the European Society of Hypertension-European Society of Cardiology guidelines from 2003. 14 No difference in 24-h ambulatory BP was observed between the two Ϫ20 A/C gene variants of the AGT (Table 2 ).
In the entire study cohort, parameters of LV structure and function did not differ between the two Ϫ20 A/C gene variants of the AGT gene. Confounding factors of LV structure, such as age, height, body mass index, physical activity, ambulatory 24-h systolic and diastolic BP, and sodium intake, were similar between the two groups ( Table 2) . BMI ϭ body mass index; BP ϭ blood pressure; Cir ϭ circumference; h/wk ϭ hours/week; n.s. ϭ not significant; VH ATCO ϭ atrial contribution to left-ventricular filling in percentages; V max A/E ϭ ratio of peak late to early velocities; VTI A/E ϭ rate of velocity time integrals. Values are mean Ϯ SD.
To explore further potential interactions between the two Ϫ20 A/C gene variants of the AGT gene and the effects of increased BP on the heart, we divided our study cohort according to hypertension status and the Ϫ20 A/C allele of the AGT gene. This analysis revealed that in hypertensive subjects with at least one copy of the Ϫ20 C allele, posterior (P ϭ .027) and septal (P ϭ .021) wall thickness, as well as LVM (P ϭ .027) and LVM index (P ϭ .048), were substantially greater than in those hypertensive subjects homozygous for the Ϫ20 A allele. Similarly, relative wall thickness (P ϭ .072) tended to be increased in subjects with at least one copy of the Ϫ20 C allele. Moreover, LV functional parameters such as midwall fractional fiber shortening (P ϭ .021) and the velocity of circumferential fiber shortening (P ϭ .013) were decreased in hypertensive subjects with at least one copy of the Ϫ20 C allele, compared with subjects homozygous for the Ϫ20 A allele. However, diastolic filling parameters did not differ between the two groups (Table 3) .
In clear contrast to the findings in hypertensive subjects, normotensive subjects demonstrated neither structural nor functional differences in LV parameters between the two gene variants of the AGT gene (Table 3) . Of note, a covariance analysis revealed that these findings could not be explained by potential confounding factors such as 24-h ambulatory BP, because these factors were similar between subjects homozygous for the Ϫ20 A allele and those with at least one copy of the Ϫ20 C allele, in both the normotensive and hypertensive groups (Table 3) .
For both genotypes (subjects homozygous for the Ϫ20 A allele and subjects with at least one copy of the Ϫ20 C allele), hypertensive subjects had a significantly greater posterior, septal, and relative wall thickness than normotensive subjects. However, only in subjects with at least one copy of the Ϫ20 C allele did hypertensive patients exhibit a greater LVM (P ϭ .007) and LVM index (P ϭ .010) than normotensive subjects. Similarly, in subjects with at least one copy of the Ϫ20 C allele, hypertensive subjects had decreased midwall fractional fiber shortening (P ϭ .001) ( Table 3 ). Since no difference existed with respect to potential confounding factors, ie, age, height, body mass index, physical activity, and sodium excretion, our results are unlikely to be affected by these factors.
Discussion
The principal finding of our study is that the Ϫ20 A/C variant of the AGT gene already modulates LV structure and function in young, male, hypertensive subjects at an early stage of hypertensive heart disease. In contrast, such modulating effects were not evident when the entire study cohort or the subgroup of normotensive subjects alone was analyzed on the basis of the Ϫ20 A/C polymorphism of the AGT gene. Of note, BP levels were similar between the two hypertensive groups with the AA and CC/CA alleles, clearly pointing toward an interaction between the Ϫ20 A/C variant of the AGT gene and hypertension status, insofar as hypertensive subjects with at least one C-allele appeared more susceptible to developing adverse structural and functional alterations of the left ventricle, compared with hypertensive subjects homozygous for the A allele.
According to our study design, ambulatory BP differed between normo-and hypertensive subjects by approximately 15/8 mm Hg. However, other potential confounding factors for LV structural and functional adaptation, such as age, height, body mass index, sodium intake, and physical activity, were similar, and thus did not evolve as major determinants of LV structural adaptation in our study cohort.
The allele frequencies of the Ϫ20 A/C polymorphism in our study cohort are in accordance with previously published data obtained from white populations. However, in agreement with the majority of previously published studies, we were unable to demonstrate an association between the level of BP and the Ϫ20 C allele of the AGT gene 11, 12, 19 in both normotensive and hypertensive subjects. The relevance of these findings is further substantiated by the use of 24-h ambulatory BP monitoring in our study, which is thought to represent the most valid tool to analyze the BP load on the left ventricle and which was not applied in previously published trials. Moreover, we examined the relationship of the Ϫ20 A/C polymorphism and LV structure and function in a very homogenous study cohort that had never been treated in the past, thereby avoiding influences of additional potential confounding factors such as choice of BP-lowering drug, dosage used, and duration of treatment.
Although it is widely appreciated that antihypertensive treatment reverses LVH, the individual responses for a given level of BP reduction vary remarkably between individuals. 20 This is clearly an aspect of clinical importance, because LVH represents a strong marker 21 of hypertensive target-organ damage, and regression of LVH by means of antihypertensive drug therapy was associated with a favorable outcome with regard to cardiovascular disease, even if BP reduction per se was taken into account. 22, 23 However, the reduction of LVM was not associated with genotypes of the Ϫ20 A/C polymorphism of the AGT gene, whereas another polymorphism, ie, the M235T variant of the AGT gene, appeared to predict the change of LVH in response to irbesartan. 24 Although these results must be interpreted cautiously because of the small sample size, the short duration of treatment (3 months), and the fact that all data were taken from one study cohort only, it is noteworthy that the 235T variant appears to be linked to the Ϫ20C polymorphism of AGT 25 and may thus complement our data. Furthermore, in a meta-analysis of patients of white origin, the 235T gene variant of the AGT gene was associated with essential hypertension 26 and with increased LVM. 24 Another important aspect that merits discussion is the linkage disequilibrium between different polymorphisms of the AGT gene. Speculatively, it is likely that the variant allele may be a marker reflecting the complex interplay of RAS genes, and that the observed genotypic effect may be caused by linkage disequilibrium with another closely linked polymorphism within the AGT gene or neighboring genes. Furthermore, haplotype analysis of the AGT gene may provide further insights and help identify those parts of the gene actively contributing to the biologic mechanisms underlying the observed changes of LV structure and function. From our data, it appears obvious that the pathogenetic role of the Ϫ20 C gene variant of the AGT gene is only unmasked in the presence of a concomitant hypertensive status. In other words, the Ϫ20 C gene variant per se does not seem to modulate LV growth, but appears to aggravate the process of LVH only if the afterload is already increased or if the renin angiotensin system is activated. 27, 28 In general, our data support the hypothesis that under certain circumstances, the gene variants of the AGT gene can emerge as determinants of LV structure and LV systolic function. However, despite a positive relationship of plasma angiotensin-converting enzyme, plasma renin activity, and plasma angiotensin II with LVH, no correlation was found between LVH and plasma AGT. 13 , 29 We did not measure plasma AGT or plasma angiotensin II, because local activity of the RAS was implicated as the more important player in pathologic changes of organ structure and function than the systemic RAS. In an experimental setting in mice overexpressing AGT exclusively in the heart, cardiac hypertrophy was induced, independent of BP alterations. However, only cardiac but not plasma angiotensin levels were increased in that setting. 30 As with any study of this kind, several restrictions and limitations apply. Our results are restricted to young, male patients with mildly or moderately elevated BP and thus cannot be extrapolated to women or older subjects. However, we believe that enrolling only young, male subjects rather strengthens our study concept for various reasons. First, although it would have been interesting to study female subjects as well, this may have influenced our results, because in women, serum AGT is strongly related to estrogen status, and the Ϫ20 A/C polymorphism modulates AGT gene transcription. 9, 31 Second, none of the patients had ever received antihypertensive or cardiovascular medication, thus ruling out any impact of previous treatment on LV structure and function. Moreover, we applied ambulatory 24-h BP to assess the hemodynamic pressure load on the LV accurately. Hence, we focused on a very homogenous study group (narrow age range, same sex, same race, and never treated), thereby decreasing the biological variability of the measured parameters. In addition, we used 24-h ambulatory BP to assess hypertension status, and two-dimensional-guided M-mode echocardiography independently evaluated by two experienced investigators to assess LV structure and function, thereby further improving chances of finding a true relationship.
In conclusion, our data demonstrate for the first time that the Ϫ20 A/C variant of the AGT gene modulates LV structure and systolic function in young, male, hypertensive patients at an early stage of hypertensive heart disease who were never previously treated or taking any concurrent antihypertensive medication. Furthermore, the impact of the Ϫ20 A/C genotype of the AGT gene on LV structure and function in hypertensive subjects appeared to be independent of other confounding factors for LV structure and function. Thus, our data support the concept that the Ϫ20 C-allele of the AGT gene is already associated with a greater degree of LVH and decreased systolic function at an early stage of hypertensive heart disease.
